Literature DB >> 16391877

Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.

Li-Sung Hsu1, Hsin-Chen Lee, Gar-Yang Chau, Pen-Hui Yin, Chin-Wen Chi, Wing Yiu Lui.   

Abstract

Epigenetic alternation via the promoter hypermethylation of putative tumor suppressor genes has been implicated in the development of hepatocellular carcinoma (HCC). In this study, we investigated the epigenetic changes in two candidate tumor suppressor genes, endothelin receptor type B (EDNRB) and p16, and their relation to the expression of these two genes in HCC. Methylation-specific polymerase chain reaction (MS-PCR) was performed to analyze the promoter methylation status of the EDNRB and p16 genes in tumors and paired non-tumor liver portions of 34 HCC patients. The mRNA expression was assessed by reverse transcription-PCR assay. Hypermethylation of the EDNRB and p16 genes was detected in 29.4% (10/34) and 32.3% (11/34) of HCC patients, respectively. Moreover, the reduction of mRNA expression was correlated to the promoter hypermethylation of the EDNRB and p16 genes. In conclusion, aberrant methylation of EDNRB and p16 genes is highly prevalent in HCC. It suggested that epigenetic alteration of the EDNRB and p16 genes may play an important role in the pathogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391877

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  21 in total

Review 1.  Early progress in epigenetic regulation of endothelin pathway genes.

Authors:  A K Welch; M E Jacobs; C S Wingo; B D Cain
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.

Authors:  Mohammad Raish; Mohsin Khurshid; Mushtaq Ahmad Ansari; Pankaj Kumar Chaturvedi; Su-Mi Bae; Jang Heub Kim; Eun Kyung Park; Dong Chun Park; Woong Shick Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-15       Impact factor: 4.553

3.  PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population.

Authors:  P S Sushma; Kaiser Jamil; P Uday Kumar; U Satyanarayana; M Ramakrishna; B Triveni
Journal:  Tumour Biol       Date:  2015-12-19

4.  Promoter hypermethylation in Indian primary oral squamous cell carcinoma.

Authors:  Jatinder Kaur; Semra Demokan; Satyendra Chandra Tripathi; Muzafar Ahmad Macha; Shahnaz Begum; Joseph A Califano; Ranju Ralhan
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

5.  Allelic loss on chromosome 5q34 is associated with poor prognosis in hepatocellular carcinoma.

Authors:  P Saelee; S Wongkham; V Bhudhisawasdi; B Sripa; S Chariyalertsak; S Petmitr
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

6.  RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level.

Authors:  Jinghua Ren; Wenshan He; Ruiguang Zhang; Zhenyu Li; Wenmiao Cao; Jie Yao; Fang Zhu; Tao Zhang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

Review 7.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

8.  Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer.

Authors:  Kaixiong Tao; Chuanqing Wu; Ke Wu; Wei Li; Gaoxiong Han; Xiaoming Shuai; Guobin Wang
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

9.  Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study.

Authors:  Soner Cander; Mutlu Karkucak; Ozen Oz Gul; Sebnem Ozemri Sag; Tahsin Yakut; Canan Ersoy; Ercan Tuncel; Erdinc Erturk
Journal:  Biomed Rep       Date:  2014-05-19

10.  Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.

Authors:  Frank Wiesmann; Jürgen Veeck; Oliver Galm; Arndt Hartmann; Manel Esteller; Ruth Knüchel; Edgar Dahl
Journal:  Breast Cancer Res       Date:  2009-06-15       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.